
Published On: Sep 2020
Published On: Sep 2020
According to a new market research study of ‘North America Liposome drug delivery Market to 2027 – Regional Analysis and Forecast by Product Type, application and technology,’ the North America Liposome drug delivery market is expected to reach US$ 2735.64 million by 2027 from US$ 1390.53million in 2019. The market is estimated to grow with a CAGR of 9.0% from 2020 to 2027. The report provides trends prevailing in the North America Liposome drug delivery market and the factors driving market along with those that act as hindrances.
Based on the product type, the North America Liposome drug delivery market is segmented into Liposomal doxorubicin, Liposomal paclitaxel, amphotericin B and others. On the basis of technology, the North American Liposomal drug delivery market is segmented into Stealth liposome technology, Depofoam liposome technology, Lysolipid thermally sensitive technology and others. And on the basis of an application it is categorized into indication in fungal diseases, cancer therapy, pain management, viral vaccines. And this market has witnessed a positive growth rate in recent periods.
Increasing Prevalence of chronic diseases, increasing demand for non-invasive drug delivery system along with rising R&D expenditures by pharmaceutical companies are some of the driving force of the market. Whereas, high cost associated with development of Non-invasive drug delivery system is about to hinder the market growth during forecast period.
Novartis AG, Luye pharma group, Ipsen pharma, Takeda Pharmaceuticals are among the leading companies operating in the North America Liposome drug delivery market.
The report segments North America Liposome Drug Delivery Market as Follows:
North America Liposome drug delivery Market – By Product Type
North America Liposome drug delivery Market – By Technology
North America Liposome drug delivery Market– By Application
North America Liposome drug delivery Market– By Country